| Autor: |
Díaz-Beyá, M, Brunet, S, Nomdedéu, J, Tejero, R, Díaz, T, Pratcorona, M, Tormo, M, Ribera, J M, Escoda, L, Duarte, R, Gallardo, D, Heras, I, Queipo de Llano, M P, Bargay, J, Monzo, M, Sierra, J, Navarro, A, Esteve, J |
| Předmět: |
|
| Zdroj: |
Leukemia (08876924); Apr2014, Vol. 28 Issue 4, p804-812, 9p, 2 Charts, 5 Graphs |
| Abstrakt: |
Acute myeloid leukemia (AML) is a heterogeneous disease, and optimal treatment varies according to cytogenetic risk factors and molecular markers. Several studies have demonstrated the prognostic importance of microRNAs (miRNAs) in AML. Here we report a potential association between miRNA expression and clinical outcome in 238 intermediate-risk cytogenetic AML (IR-AML) patients from 16 institutions in the CETLAM cooperative group. We first profiled 670 miRNAs in a subset of 85 IR-AML patients from a single institution and identified 10 outcome-related miRNAs. We then validated these 10 miRNAs by individual assays in the total cohort and confirmed the prognostic impact of 4 miRNAs. High levels of miR-196b and miR-644 were independently associated with shorter overall survival, and low levels of miR-135a and miR-409-3p with a higher risk of relapse. Interestingly, miR-135a and miR-409-3p maintained their independent prognostic value within the unfavorable molecular subcategory (wild-type NPM1 and CEBPA and/or FLT3-ITD), and miR-644 retained its value within the favorable molecular subcategory. miR-409-3p, miR-135a, miR-196b and mir-644 arose as prognostic markers for IR-AML, both overall and within specific molecular subgroups. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
